Similar articles

• How common is attention-deficit/hyperactivity disorder? Incidence in a population-based birth cohort in Rochester, Minn.

  Barbaresi WJ, Katusic SK, Colligan RC, Pankratz VS, Weaver AL, Weber KJ, Mrazek DA, Jacobsen SJ. Barbaresi WJ, et al. Arch Pediatr Adolesc Med. 2002 Mar;156(3):217-24. doi: 10.1001/archpedi.156.3.217. Arch Pediatr Adolesc Med. 2002. PMID: 11876664
• Use, abuse, toxicity, and monitoring of pediatric psychotropic drug therapy: new issues for the new millennium.

  Liebelt EL. Liebelt EL. Curr Opin Pediatr. 2002 Apr;14(2):211-2. doi: 10.1097/00008480-200204000-00011. Curr Opin Pediatr. 2002. PMID: 11981292 Review. No abstract available.
• Psychotropic drug use among preschool children in the Medicaid program from 36 states.

  Garfield LD, Brown DS, Allaire BT, Ross RE, Nicol GE, Raghavan R. Garfield LD, et al. Am J Public Health. 2015 Mar;105(3):524-9. doi: 10.2105/AJPH.2014.302258. Epub 2015 Jan 20. Am J Public Health. 2015. PMID: 25602884 Free PMC article.
• Utilization of Stimulants and Atomoxetine for Attention-Deficit/Hyperactivity Disorder among 5.4 Million Children Using Population-Based Longitudinal Data.

  Furu K, Karlstad Ø, Zoega H, Martikainen JE, Bahmanyar S, Kieler H, Pottegård A. Furu K, et al. Basic Clin Pharmacol Toxicol. 2017 Apr;120(4):373-379. doi: 10.1111/bcpt.12724. Epub 2017 Jan 30. Basic Clin Pharmacol Toxicol. 2017. PMID: 27911044
• Psychopharmacotherapy of Attention Deficit-Hyperactivity Disorder in Children with Comorbid Conditions.

  Naguy A. Naguy A. Pediatr Neurol. 2018 May;82:7-12. doi: 10.1016/j.pediatrneurol.2017.09.010. Epub 2017 Sep 27. Pediatr Neurol. 2018. PMID: 29678368 Review.